Related Experiment Video
Updated: Sep 13, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
[An Intestinal Metabolite Exacerbates Stress-induced Diarrhea]
Narumi Ishihara1, Shunsuke Kimura1, Koji Hase1,2
1Faculty of Pharmacy, Keio University.
None:
Irritable bowel syndrome (IBS) constitutes a chronic functional gastrointestinal disorder characterized by abdominal pain and irregular bowel habits. Diagnosis typically hinges upon symptomatology, following the exclusion of organic pathologies such as intestinal inflammation and malignancies. IBS manifests with diverse symptoms attributable to aberrant intestinal function, including diarrhea, constipation, and bloating, stratified into four types based on the predominance of diarrhea versus constipation. Radical treatment for IBS remains elusive due to its unknown pathology and etiology, thereby necessitating symptom-focused therapeutic approaches. Certain conditions such as psychiatric disorders, intestinal inflammation, food sensitivities, and Small Intestinal Bacterial Overgrowth (SIBO) exhibit overlaps with or correlations to symptoms of IBS, suggesting that treatment targeting these conditions may ameliorate symptoms of IBS. Emotional stress emerges as a principal risk factor for IBS, precipitating alterations in stress hormone levels and intestinal motility, thereby instigating a spectrum of symptoms associated with the disorder. Additional risk factors for IBS exhibit considerable variability among individuals, encompassing dietary factors that stimulate or influence intestinal function, gluten, the presence of fermentable carbohydrates (fermentable oligosaccharides disaccharides monosaccharides and polyols: FODMAPs), and aspects of the intestinal microbiota and its metabolites. Notably, individuals with IBS demonstrate distinctive alterations in gut microbiota composition compared to healthy controls, indicative of dysbiosis. Furthermore, changes in metabolites such as short-chain fatty acids (SCFAs) in some IBS patients are recognized. In summary, while the precise etiology and underlying pathology of IBS remain elusive, management typically necessitates a multifaceted approach involving lifestyle modifications, targeted symptom therapies, occasional psychological support, and adjunctive measures to regulate the intestinal environment.
Related Concept Videos
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

